Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Trechot P. Comment on “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00784-y.

    Article  PubMed  Google Scholar 

  2. 2.

    Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00747-3(epub 4 Apr 2019).

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Aronson JK, La Caze A, Kelly MP, Parkkinen V-P, Williamson J. The use of mechanistic evidence in drug approval. J Eval Clin Pract. 2018;24:1166–76.

    Article  Google Scholar 

  4. 4.

    Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.

    Article  Google Scholar 

  5. 5.

    Chen M-L, Sadrieh N, Yu L. Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs. AAPS J. 2013;15:1043–50.

    Article  Google Scholar 

  6. 6.

    Shah HS, Chaturvedi K, Hamad M, Bates S, Hussain A, Morris K. New insights on solid-state changes in the levothyroxine sodium pentahydrate during dehydration and its relationship to chemical instability. AAPS PharmSciTech. 2019;20:39.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pierre-Louis Toutain.

Ethics declarations

Funding

No sources of funding were used in the preparation of this reply.

Conflict of interest

Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain declare no relevant potential conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Concordet, D., Gandia, P., Montastruc, J. et al. Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet 58, 979–980 (2019). https://doi.org/10.1007/s40262-019-00787-9

Download citation